Marker Therapeutics Inc (MRKR): Benzinga also had a report on MRKR on 7-...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	13
Posts	1546
Boards Moderated	0
Alias Born	06/14/2018

microcapbiotech

Re: None

Tuesday, 07/18/2023 2:44:59 PM

Tuesday, July 18, 2023 2:44:59 PM

Benzinga also had a report on MRKR on 7-11.
"What's Going On With Marker Therapeutics (MRKR) Stock"
"Marker Therapeutics, Inc. (NASDAQ: MRKR) shares are trading higher by 3.0% to $5.50 Tuesday morning. The stock is rising on continued momentum after the company on Monday announced the European Medicines Agency granted MT-401 an Orphan Drug Designation.
The drug is for the treatment of patients with acute myeloid leukemia (AML). Per Marker, AML is a life-threatening disease with high relapse rates and poor outcomes after hematopoietic stem cell transplant (HSCT).
MT-401 is designed to target multiple tumor-associated antigens and is currently being evaluated in a Phase 2 clinical trial for relapsed AML post-HSCT. Orphan Drug Designation provides regulatory support, including market exclusivity, reduced fees and scientific advice from the EMA."